Pharma has a misinformation problem — and execs could be on the hook

In 2022, a writer for a progressive magazine wanted to make a statement about the cost of drugs in the U.S. So, he sent out a tweet from a false Eli Lilly account claiming insulin was free.

The tweet went viral and although the writer later said he never thought anyone would think it was real, the fake statement had major consequences for Lilly. Within a few hours, the uproar triggered a $23 billion sell-off of Lilly’s stock, which eroded its market cap by over 6%.